Voglibose

Voglibose is a valiolamine derivative & inhibitor of alpha-glucosidase with antihyperglycemic activity. Voglibose binds to & inhibits alpha-glucosidase, an enteric enzyme found in the brush border of the small intestines that hydrolyzes oligosaccharides & disaccharides into- glucose & other monosaccharides. This prevents the breakdown of larger carbohydrates into glucose & decreases the rise in post- prandial blood glucose levels. Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.
Voglibose is orally active maltase-glucoamylase (α-glucosidase) inhibitor (ic50 values are 3.9 & 6.4 nm at sucrase & maltase respectively). It increases glucagon-like peptide 1 (glp-1) secretion and also decreases food consumption in obob mice. Voglibose reduces plasma concentration of glucose, triglycerides and insulin in wistar fatty rats additionally, voglibose exhibits antidiabetic and antiobesity activity in vivo.